(RTTNews) - KALA Bio, Inc. (KALA) on Monday announced that its CHASE Phase 2b study of KPI-012 for the treatment of persistent corneal epithelial defect (PCED) did not meet the primary endpoint of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback